Adria Cimino from Motley Fool - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Adria Cimino Motley Fool Writer, biotech, consumer goods. @themotleyfool contributor. Paris, France biotechnologyconsumer goodsinvesting		Should You Forget Nvidia and Buy This Artificial Intelligence (AI) Stock Right Now? - about 1 month ago Could Investing $10,000 in Palantir Make You a Millionaire? - 2 months ago Better Stock-Split Buy: Nvidia vs. Super Micro Computer - 2 months ago Better Stock-Split Buy: Broadcom vs. Chipotle - 4 months ago Amazon: Buy, Sell or Hold? - 4 months ago The S&P 500 Soared Nearly 15% in the 1st Half. History Says This Will Happen Next. - 4 months ago Here Are My Top 2 Magnificent Seven Stocks to Buy Hand Over Fist - 5 months ago Forget Disney: Buy This Unstoppable Growth Stock Instead - 6 months ago Ready to Invest in Artificial Intelligence (AI)? 2 Stocks That Are Solid Bets. - 7 months ago History Says the Nasdaq Will Soar This Year: My Top Artificial Intelligence (AI) Growth Stocks to Buy Before It Does - 8 months ago Stock Split Watch: Could Super Micro Computer Be Next? - 8 months ago 2 "Magnificent Seven" Stocks to Buy Hand Over Fist Right Now - 8 months ago What's the Best Way to Invest in Stocks Without Any Experience? Start With This Index Fund. - 8 months ago Forget Nvidia: Another "Magnificent Seven" Artificial Intelligence (AI) Powerhouse Is Cheaper - 8 months ago 2 Dividend Stocks to Double Up On Right Now - 8 months ago 2 Artificial Intelligence (AI) Stocks You Can Buy and Hold for the Next Decade - 8 months ago This Phenomenal Artificial Intelligence (AI) Growth Stocks Turned $100,000 Into More Than $600,000. Could It Do It Again? - 9 months ago Looking for Growth and Dividends? Try These 2 Top "Magnificent Seven" Stocks - 9 months ago 2 Unstoppable Artificial Intelligence (AI) Stocks Up More Than 200% to Buy and Hold for the Long Term - 9 months ago Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market? - 9 months ago The Ultimate AI Growth Stock to Buy With $500 - 9 months ago This 1 Number Points to Apple's Next Growth Driver - 9 months ago My 2 Favorite Stocks to Buy Right Now - 9 months ago Meta Is Making AI Investment a Priority in 2024. Time to Buy? - 10 months ago 5 Top Investing Resolutions for 2024 - 11 months ago After a Record Quarter and Year, Is Carnival a Buy? - 11 months ago 5 Top Stocks to Buy With Your End-of-the-Year Bonus - 11 months ago Is Vertex Pharmaceuticals Sitting on a Gold Mine? - 11 months ago Warren Buffett Just Sold Shares of This Stock-Split Stock. Should You? - 11 months ago After This Landmark Win, Is CRISPR Therapeutics a Buy? - 11 months ago 3 No-Brainer Healthcare Stocks to Buy Right Now - 11 months ago Toast Stock: Buy, Sell, or Hold? - 11 months ago 5 No-Brainer Stocks to Buy Before 2024 - 11 months ago Is This News a Setback or a Step Forward for CRISPR Therapeutics? - 12 months ago The Market Has Rallied This Year. Should You Pile Into Growth Stocks in December? - 12 months ago 5 Top Stocks to Buy Before 2024 - 12 months ago Looking for Growth? 2 Top Stocks to Buy Hand Over Fist - 12 months ago 3 Things You Shouldn't Do if the Stock Market Crashes - 12 months ago 2 Consumer Goods Stocks That Could Make You a Lot Richer Than Coca-Cola Will - 12 months ago Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now - 12 months ago 2 Growth Stocks to Buy Before the Big Bull Rally - 12 months ago 2 No-Brainer Stocks to Buy That'll Make You Rich in 2024 and Beyond - 12 months ago Instacart's First Post-IPO Earnings Report Looked Promising. Should Investors Buy the Stock? - 12 months ago The Best Warren Buffett Stocks to Buy With $300 Right Now - 12 months ago You Don't Have to Pick a Winner in Biotech. Here's Why. - 12 months ago Can CRISPR Therapeutics Stock Double in 5 Years? Here's What It Would Take. - about 1 year ago AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? - about 1 year ago 3 Cathie Wood Bargain Buys That Should Be on Your List Too - about 1 year ago Down 45%, Is Intellia a Buy? - about 1 year ago Did Moderna Just Jump Ahead of Rivals in a Potential Billion-Dollar Market? - about 1 year ago